Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss

NCT07666126 | Recruiting

• 1 other identifier: 2025/302
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism. A total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.

Conditions

Periodontal Diseases; Hyperuricemia; Oxidative Stress

Keywords

periodontal disease; hyperuricemia; oxidative stress; alveolar bone loss; inflammation

Outcome Measures

Primary Outcomes (2)

• Periodontal pocket depth

  The distance between the gingival margin and the base of the pocket will be measured in millimeters.

  at baseline

• clinical attachment loss

  The distance between the enamel-cementum junction and the base of the pocket will be measured in millimeters.

  at baseline

Secondary Outcomes (3)

• Level of interleukin-1 beta

  at baseline

• Level of interleukin-10

  at baseline

• Level of interleukin-18

  at baseline

Study Arms (4)

Group 1: Individuals with periodontitis and hyperuricemia

Other: Collection of gingival crevicular fluid (GCF) and serum samples; Other: Measurement of periodontal clinical parameters

Group 2: Periodontally healthy individuals with hyperuricemia

Other: Collection of gingival crevicular fluid (GCF) and serum samples; Other: Measurement of periodontal clinical parameters

Group 3: Individuals with periodontitis but without hyperuricemia

Other: Collection of gingival crevicular fluid (GCF) and serum samples; Other: Measurement of periodontal clinical parameters

Group 4: Periodontally healthy individuals without hyperuricemia

Other: Collection of gingival crevicular fluid (GCF) and serum samples; Other: Measurement of periodontal clinical parameters

Interventions

Collection of gingival crevicular fluid (GCF) and serum samples OTHER

Serum and GCF samples will be collected from participants in the first session

Group 1: Individuals with periodontitis and hyperuricemia; Group 2: Periodontally healthy individuals with hyperuricemia; Group 3: Individuals with periodontitis but without hyperuricemia; Group 4: Periodontally healthy individuals without hyperuricemia

Measurement of periodontal clinical parameters OTHER

Periodontal clinical parameters will be measured from participants initially

Group 1: Individuals with periodontitis and hyperuricemia; Group 2: Periodontally healthy individuals with hyperuricemia; Group 3: Individuals with periodontitis but without hyperuricemia; Group 4: Periodontally healthy individuals without hyperuricemia

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Recep Tayyip Erdoğan University Faculty of Dentistry

You may qualify if:

• Being between 18 and 65 years of age
• Being systemically healthy or diagnosed with hyperuricemia
• Having at least 20 natural teeth
• Being periodontally healthy or diagnosed with periodontitis

You may not qualify if:

• Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.
• Smoking
• Pregnancy or lactation
• Having received periodontal treatment within the last 3-6 months
• Use of antibiotics, anti-inflammatory drugs, or uric acid-lowering drugs
• Presence of systemic diseases that may affect purine metabolism

Sponsors & Collaborators

• Recep Tayyip Erdogan University Training and Research Hospital: lead

Study Sites (1)

Recep Tayyip Erdoğan University

Rize, 53020, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Periodontal Diseases; Hyperuricemia; Alveolar Bone Loss; Inflammation

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Bone Resorption; Bone Diseases; Musculoskeletal Diseases; Periodontal Atrophy

Central Study Contacts

Hatice Yemenoglu

CONTACT

+905052977517; htcymnglu@hotmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: June 8, 2026
• First Posted: June 24, 2026
• Study Start: June 10, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: June 26, 2026

Record last verified: 2026-06

Locations

TU (1)